Home ETF List About

Portfolio Holdings Detail for ISIN IE00BFNM3H51
Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /var/www/liquidata/show_ticker_holding_ETFs.php on line 77
Stock Name / FundiShares MSCI USA ESG Screened UCITS ETF USD (Dist)
IssuerBlackrock
ETF TickerSDUS(USD) LSE
ETF TickerSLUS(EUR) F
ETF TickerSDUS.LS(USD) CXE
ETF TickerSLUS.DE(EUR) CXE
ETF TickerSDUS.L(GBP) LSE

Holdings detail for NBIX

Stock NameNeurocrine Biosciences Inc
TickerNBIX(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS64125C1099
LEI549300FECER0XBN49756

Show aggregate NBIX holdings

News associated with NBIX

Sum Up The Parts: SCHG Could Be Worth $34
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-08-21 10:23:31
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by Maryland State Retirement & Pension System
Maryland State Retirement & Pension System lowered its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 12.5% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 4,661 shares of the company’s stock after selling 663 shares during the quarter. Maryland […] - 2025-08-15 05:24:56
Charles Schwab Investment Management Inc. Purchases 13,216 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)
Charles Schwab Investment Management Inc. raised its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 1.7% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 775,773 shares of the company’s stock after acquiring an additional 13,216 shares during the quarter. Charles […] - 2025-08-13 05:10:46
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by Blair William & Co. IL
Blair William & Co. IL cut its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 3.7% in the first quarter, Holdings Channel reports. The fund owned 6,214 shares of the company’s stock after selling 242 shares during the period. Blair William & Co. IL’s holdings in Neurocrine Biosciences were worth $687,000 at the […] - 2025-08-11 05:52:52
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by Federated Hermes Inc.
Federated Hermes Inc. trimmed its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 72.9% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 9,441 shares of the company’s stock after selling 25,402 shares during the quarter. Federated Hermes Inc.’s […] - 2025-08-07 05:22:58
Natixis Advisors LLC Sells 292 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)
Natixis Advisors LLC lowered its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 0.9% in the first quarter, Holdings Channel.com reports. The institutional investor owned 33,312 shares of the company’s stock after selling 292 shares during the period. Natixis Advisors LLC’s holdings in Neurocrine Biosciences were worth $3,684,000 at the end of the […] - 2025-08-07 04:49:07
Neurocrine (NBIX) Q2 2025 Earnings Call Transcript
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo - 2025-08-05 01:16:10
Neurocrine (NBIX) Q2 Revenue Jumps 17%
Key PointsNon-GAAP earnings per share of $1.65 for Q2 2025 vastly exceeded the analyst estimate of $0.96. - 2025-08-01 01:15:16
13,202 Shares in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Bought by Y Intercept Hong Kong Ltd
Y Intercept Hong Kong Ltd acquired a new position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) in the 1st quarter, HoldingsChannel.com reports. The fund acquired 13,202 shares of the company’s stock, valued at approximately $1,460,000. Other hedge funds and other institutional investors have also recently bought and sold shares of the company. […] - 2025-07-24 06:50:57
HighPoint Advisor Group LLC Purchases 366 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)
HighPoint Advisor Group LLC boosted its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 15.0% during the first quarter, Holdings Channel.com reports. The fund owned 2,812 shares of the company’s stock after acquiring an additional 366 shares during the quarter. HighPoint Advisor Group LLC’s holdings in Neurocrine Biosciences were worth $302,000 […] - 2025-07-24 05:51:14
Neurocrine Biosciences (NASDAQ:NBIX) Now Covered by Analysts at Truist Financial
Truist Financial initiated coverage on shares of Neurocrine Biosciences (NASDAQ:NBIX – Free Report) in a research report report published on Monday, Marketbeat reports. The firm issued a buy rating and a $163.00 price target on the stock. NBIX has been the subject of several other reports. Royal Bank Of Canada reaffirmed an “outperform” rating and […] - 2025-07-22 04:28:48
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Position Trimmed by Cerity Partners LLC
Cerity Partners LLC decreased its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 20.1% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 33,361 shares of the company’s stock after selling 8,376 shares during the quarter. Cerity Partners LLC’s holdings in […] - 2025-07-18 04:55:08
Ingrid Delaet Sells 457 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Stock
Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Free Report) insider Ingrid Delaet sold 457 shares of the business’s stock in a transaction on Thursday, July 10th. The stock was sold at an average price of $135.00, for a total transaction of $61,695.00. Following the completion of the transaction, the insider directly owned 4,730 shares in the […] - 2025-07-14 07:16:47
Bank of New York Mellon Corp Has $91.65 Million Stock Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)
Bank of New York Mellon Corp lessened its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 4.8% during the first quarter, HoldingsChannel reports. The fund owned 828,682 shares of the company’s stock after selling 41,608 shares during the quarter. Bank of New York Mellon Corp’s holdings in Neurocrine Biosciences were worth $91,652,000 as […] - 2025-07-11 05:40:57
Principal Financial Group Inc. Has $27.48 Million Stock Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)
Principal Financial Group Inc. reduced its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 1.6% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 248,420 shares of the company’s stock after selling 4,049 shares during the period. Principal Financial Group Inc. owned 0.25% of Neurocrine Biosciences […] - 2025-07-09 05:51:40
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Given Average Recommendation of “Moderate Buy” by Analysts
Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the twenty-two brokerages that are presently covering the stock, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a hold recommendation and nineteen have given a buy recommendation to the company. The average 12 […] - 2025-07-09 03:09:50
First Horizon Advisors Inc. Has $43,000 Stock Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)
First Horizon Advisors Inc. decreased its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 55.5% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 385 shares of the company’s stock after selling 480 shares during the quarter. First Horizon Advisors […] - 2025-07-08 05:49:06
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Insider Jude Onyia Sells 20,362 Shares
Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Free Report) insider Jude Onyia sold 20,362 shares of the company’s stock in a transaction on Wednesday, July 2nd. The stock was sold at an average price of $130.13, for a total value of $2,649,707.06. Following the completion of the sale, the insider owned 18,289 shares of the company’s […] - 2025-07-08 05:06:50
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by KBC Group NV
KBC Group NV lessened its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 3.5% in the 1st quarter, Holdings Channel reports. The fund owned 13,835 shares of the company’s stock after selling 495 shares during the period. KBC Group NV’s holdings in Neurocrine Biosciences were worth $1,530,000 as of its most recent filing […] - 2025-07-04 06:58:45
New York State Teachers Retirement System Lowers Stock Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)
New York State Teachers Retirement System lowered its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 1.9% during the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 108,481 shares of the company’s stock after selling 2,055 shares during the quarter. New York State Teachers Retirement System’s holdings in Neurocrine Biosciences were worth $11,998,000 […] - 2025-07-04 06:14:58
Amalgamated Bank Has $5.28 Million Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)
Amalgamated Bank lessened its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 3.8% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 47,719 shares of the company’s stock after selling 1,895 shares during the quarter. Amalgamated Bank’s holdings in Neurocrine Biosciences were […] - 2025-07-03 06:14:49
Sumitomo Mitsui Trust Group Inc. Sells 1,399 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)
Sumitomo Mitsui Trust Group Inc. reduced its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 0.6% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 231,458 shares of the company’s stock after selling 1,399 shares during the quarter. Sumitomo Mitsui Trust […] - 2025-07-03 05:35:01
Golden State Wealth Management LLC Grows Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)
Golden State Wealth Management LLC increased its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 116.9% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 397 shares of the company’s stock after purchasing an additional 214 shares during the quarter. […] - 2025-07-02 05:01:01
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Acquired by Oppenheimer & Co. Inc.
Oppenheimer & Co. Inc. raised its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 2.4% in the 1st quarter, HoldingsChannel.com reports. The fund owned 19,388 shares of the company’s stock after buying an additional 447 shares during the quarter. Oppenheimer & Co. Inc.’s holdings in Neurocrine Biosciences were worth $2,144,000 as […] - 2025-06-27 05:10:49
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by Retirement Systems of Alabama
Retirement Systems of Alabama cut its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 1.4% in the 1st quarter, Holdings Channel reports. The firm owned 121,352 shares of the company’s stock after selling 1,755 shares during the period. Retirement Systems of Alabama’s holdings in Neurocrine Biosciences were worth $13,422,000 at the […] - 2025-06-23 05:04:51
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Bought by QRG Capital Management Inc.
QRG Capital Management Inc. lifted its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 7.1% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 20,062 shares of the company’s stock after buying an additional 1,330 shares […] - 2025-06-20 06:54:59
Sowell Financial Services LLC Takes Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)
Sowell Financial Services LLC bought a new stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 4,786 shares of the company’s stock, valued at approximately $529,000. Other institutional investors and hedge funds […] - 2025-06-20 05:29:06
Trust Point Inc. Sells 660 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)
Trust Point Inc. decreased its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 26.6% in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,823 shares of the company’s stock after selling 660 shares during the period. Trust Point Inc.’s holdings in […] - 2025-06-19 05:35:02
XBI, EXAS, NBIX, NTRA: ETF Outflow Alert
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approximate $443.9 million dollar outflow -- that's a 8.8% decrease week over week - 2025-06-17 11:54:37
Merit Financial Group LLC Acquires 345 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)
Merit Financial Group LLC raised its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 9.1% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,153 shares of the company’s stock after purchasing an additional 345 shares during the quarter. Merit Financial Group […] - 2025-06-11 05:00:51

iShares MSCI USA ESG Screened UCITS ETF USD (Dist) NBIX holdings

DateNumber of NBIX Shares HeldBase Market Value of NBIX SharesLocal Market Value of NBIX SharesChange in NBIX Shares HeldChange in NBIX Base ValueCurrent Price per NBIX Share HeldPrevious Price per NBIX Share Held
2025-09-30 (Tuesday)28,716NBIX holding increased by 438USD 4,031,152NBIX holding increased by 64597USD 4,031,152438USD 64,597 USD 140.38 USD 140.27
2025-09-29 (Monday)28,278NBIX holding increased by 114USD 3,966,555NBIX holding decreased by -32733USD 3,966,555114USD -32,733 USD 140.27 USD 142
2025-09-26 (Friday)28,164NBIX holding increased by 258USD 3,999,288NBIX holding increased by 67612USD 3,999,288258USD 67,612 USD 142 USD 140.89
2025-09-25 (Thursday)27,906NBIX holding increased by 18USD 3,931,676NBIX holding decreased by -158657USD 3,931,67618USD -158,657 USD 140.89 USD 146.67
2025-09-24 (Wednesday)27,888USD 4,090,333USD 4,090,333
2025-09-18 (Thursday)27,546NBIX holding increased by 72USD 4,012,350NBIX holding increased by 90986USD 4,012,35072USD 90,986 USD 145.66 USD 142.73
2025-09-17 (Wednesday)27,474NBIX holding increased by 90USD 3,921,364NBIX holding increased by 62958USD 3,921,36490USD 62,958 USD 142.73 USD 140.9
2025-09-16 (Tuesday)27,384NBIX holding increased by 144USD 3,858,406NBIX holding increased by 32820USD 3,858,406144USD 32,820 USD 140.9 USD 140.44
2025-09-15 (Monday)27,240USD 3,825,586USD 3,825,586
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of NBIX by Blackrock for IE00BFNM3H51

Show aggregate share trades of NBIX

DateActionQuantityMarket HighMarket LowLikely Trade PriceLikely Trade Value (Profit/Loss)Average Price previous trades
2025-09-30BUY438 140.380* 121.35
2025-09-29BUY114 140.270* 121.24
2025-09-26BUY258 142.000* 121.13
2025-09-25BUY18 140.890* 121.02
2025-09-18BUY72 145.660* 120.88
2025-09-17BUY90 142.730* 120.76
2025-09-16BUY144 140.900* 120.65
2025-08-15BUY12 132.900* 120.51
2025-08-13BUY7 131.620* 120.44
2025-08-08BUY54 125.010* 120.42
2025-08-06BUY114 128.430* 120.34
2025-07-31BUY30 128.230* 120.25
2025-07-29BUY120 134.190* 120.06
2025-07-11BUY48 133.460* 119.98
2025-07-10BUY54 134.920* 119.89
2025-07-09BUY54 133.510* 119.81
2025-07-07SELL-36 127.880* 119.71 Profit of 4,309 on sale
2025-07-02SELL-150 129.400* 119.53 Profit of 17,929 on sale
2025-06-27BUY23 125.420* 119.45
2025-06-26BUY18 126.710* 119.41
2025-06-24SELL-84 128.180* 119.30 Profit of 10,021 on sale
2025-06-18BUY48 127.310* 119.10
2025-06-17BUY18 124.880* 119.06
2025-06-16SELL-24 125.000* 119.02 Profit of 2,857 on sale
2025-06-12SELL-30 125.010* 118.98 Profit of 3,569 on sale
2025-06-11BUY66 124.170* 118.95
2025-06-06BUY18 125.390* 118.81
2025-06-05BUY84 124.610* 118.77
2025-06-04BUY12 124.520* 118.73
2025-06-03SELL-6 125.000* 118.69 Profit of 712 on sale
2025-05-30SELL-732 123.020* 118.61 Profit of 86,825 on sale
2025-05-29BUY18 123.660* 118.58
2025-05-27BUY102 122.640* 118.51
2025-05-23BUY90 120.180* 118.49
2025-05-22BUY42 119.120* 118.49
2025-05-19BUY36 122.820* 118.40
2025-05-16BUY18 121.020* 118.38
2025-05-15SELL-12 120.270* 118.37 Profit of 1,420 on sale
2025-05-14BUY6 118.780* 118.36
2025-05-13BUY12 116.870* 118.37
2025-05-12BUY42 120.430* 118.36
2025-05-09SELL-30 115.710* 118.38 Profit of 3,551 on sale
2025-05-08BUY12 117.520* 118.39
2025-05-07BUY18 121.610* 118.36
2025-05-02BUY666 109.680* 118.50
2025-04-30BUY210 107.690* 118.70
2025-04-29BUY54 107.240* 118.79
2025-04-28BUY42 106.460* 118.90
2025-04-25BUY108 106.730* 119.01
2025-04-24SELL-126 105.760* 119.13 Profit of 15,010 on sale
2025-04-23BUY114 103.220* 119.27
2025-04-22BUY48 101.740* 119.43
2025-04-17BUY66 101.380* 119.93
2025-04-15BUY60 96.160* 120.34
2025-04-11BUY96 90.870* 120.87
2025-04-09BUY36 95.280* 121.42
2025-04-08BUY216 87.540* 121.75
2025-04-07BUY72 93.250* 122.04
2025-04-04SELL-96 95.650* 122.31 Profit of 11,741 on sale
2025-04-02BUY816 108.310* 122.45
2025-04-01BUY6 107.000* 122.61
2025-03-31BUY42 110.600* 122.73
2025-03-28BUY24 113.160* 122.83
2025-03-27BUY12 114.000* 122.93
2025-03-26BUY6 114.450* 123.02
2025-03-25BUY66 116.180* 123.09
2025-03-24BUY78 115.600* 123.18
2025-03-21SELL-24 111.920* 123.30 Profit of 2,959 on sale
2025-03-20BUY96 110.070* 123.45
2025-03-19BUY18 110.310* 123.60
2025-03-18BUY216 109.700* 123.76
2025-03-17BUY42 111.500* 123.90
2025-03-14BUY312 110.750* 124.06
2025-03-13BUY60 108.990* 124.24
2025-03-12SELL-300 109.070* 124.42 Profit of 37,325 on sale
2025-03-11SELL-222 107.220* 124.63 Profit of 27,667 on sale
2025-03-10BUY66 110.870* 124.80
2025-03-07BUY12 113.040* 124.94
2025-03-05BUY90 113.850* 125.08
2025-03-04BUY102 113.110* 125.24
2025-03-03BUY192 114.480* 125.38
2025-02-28BUY156 118.720* 125.47
2025-02-27SELL-30 117.510* 125.57 Profit of 3,767 on sale
2025-02-25BUY222 115.900* 125.81
2025-02-21BUY24 120.690* 125.98
2025-02-18SELL-54 113.970* 126.47 Profit of 6,830 on sale
2025-02-14SELL-366 115.020* 126.82 Profit of 46,417 on sale
2025-02-13BUY6 116.870* 126.97
2025-02-12BUY60 117.180* 127.13
2025-02-07SELL-6 122.620* 127.51 Profit of 765 on sale
2025-02-06BUY114 150.510* 127.12
2025-02-05BUY30 151.200* 126.71
2025-02-04BUY36 152.420* 126.27
2025-02-03BUY36 150.100* 125.85
2025-01-31BUY66 151.820* 125.39
2025-01-29SELL-6 150.680* 124.41 Profit of 746 on sale
2025-01-28SELL-54 150.710* 123.91 Profit of 6,691 on sale
2025-01-27SELL-96 148.190* 123.44 Profit of 11,850 on sale
2025-01-24BUY72 148.730* 122.95
2025-01-23BUY12 147.580* 122.45
2024-12-10BUY300 128.960* 122.32
2024-12-09BUY36 129.120* 122.18
2024-12-06SELL-90 128.140* 122.05 Profit of 10,985 on sale
2024-12-05SELL-6 126.420* 121.96 Profit of 732 on sale
2024-12-03BUY30 125.440* 121.75
2024-11-27SELL-36 126.590* 121.28 Profit of 4,366 on sale
2024-11-26BUY126 127.910* 120.93
2024-11-26BUY126 127.910* 120.93
2024-11-25BUY15 127.110* 120.76
2024-11-22SELL-12 125.650* 120.62 Profit of 1,447 on sale
2024-11-21SELL-30 125.000* 120.50 Profit of 3,615 on sale
2024-11-20SELL-12 123.290* 120.42 Profit of 1,445 on sale
2024-11-19BUY6 119.130* 120.46
2024-11-18BUY52 117.620* 120.54
2024-11-11BUY18 127.170* 119.86
2024-11-11BUY18 127.170* 119.86
2024-11-07BUY18 123.980* 119.06
2024-11-07BUY18 123.980* 119.06
2024-11-06BUY144 125.300* 118.52
2024-11-06BUY144 125.300* 118.52
2024-11-05BUY30 121.530* 118.24
2024-11-05BUY30 121.530* 118.24
2024-11-04BUY12 120.530* 117.99
2024-11-04BUY12 120.530* 117.99
2024-11-01BUY18 122.210* 117.50
2024-11-01BUY18 122.210* 117.50
2024-10-30SELL-36 124.330* 116.02 Profit of 4,177 on sale
2024-10-30SELL-36 124.330* 116.02 Profit of 4,177 on sale
2024-10-29SELL-108 116.190* 115.99 Profit of 12,527 on sale
2024-10-29SELL-108 116.190* 115.99 Profit of 12,527 on sale
2024-10-28SELL-42 116.200* 115.94 Profit of 4,870 on sale
2024-10-28SELL-42 116.200* 115.94 Profit of 4,870 on sale
2024-10-21SELL-6 116.570* 0.00
Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of NBIX

DateShorted VolumeShort Exempt VolumeTotal Shares Traded% Shorted
2025-09-19138,3040280,71449.3%
2025-09-18207,77644,506326,19463.7%
2025-09-17106,323343194,59754.6%
2025-09-1697,81119,146256,98038.1%
2025-09-1573,3630197,45737.2%
2025-09-1271,8171,305193,96837.0%
2025-09-1187,2040250,36934.8%
2025-09-10117,0990288,60540.6%
2025-09-09123,3791,879226,94154.4%
2025-09-08213,6691,667350,78760.9%
2025-09-05269,8828,988447,93060.3%
2025-09-04193,322481275,12970.3%
2025-09-03210,597108556,90537.8%
2025-09-02183,31915,512318,15057.6%
2025-08-29101,0617,590154,07965.6%
2025-08-28127,383487193,56165.8%
2025-08-27137,4541,818217,03363.3%
2025-08-26170,0223,558291,09658.4%
2025-08-25124,1533,639195,47663.5%
2025-08-22126,62910,885196,28864.5%
2025-08-21119,2451,265200,99059.3%
2025-08-20135,1384,637230,01058.8%
2025-08-19186,010535287,33064.7%
2025-08-18162,0387,351232,60969.7%
2025-08-15140,024100220,19963.6%
2025-08-14290,907253363,13980.1%
2025-08-13356,4048,730466,19176.5%
2025-08-12303,9754,067434,64169.9%
2025-08-11279,1915,617413,02767.6%
2025-08-08338,3850490,22069.0%
2025-08-07341,7192486,06070.3%
2025-08-06162,49452290,74155.9%
2025-08-05127,812122285,40144.8%
2025-08-04184,650798554,60133.3%
2025-08-01384,652274613,13762.7%
2025-07-31795,02721,403,51956.6%
2025-07-30277,359199566,94248.9%
2025-07-29235,4831,232479,50449.1%
2025-07-28128,7961,272304,76342.3%
2025-07-25164,9590533,68230.9%
2025-07-24143,137442360,99139.7%
2025-07-23127,087250336,56737.8%
2025-07-22110,378700199,61455.3%
2025-07-2194,76891171,48155.3%
2025-07-18136,185216238,83657.0%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.